Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells
- 0
Angelman Syndrome is a uncommon neurodevelopmental dysfunction characterised by impaired communication expertise, ataxia, motor and steadiness deficits, mental disabilities, and seizures. The genetic reason for Angelman syndrome is the neuronal lack of UBE3A expression within the mind.
A novel method, described right here, is a stem cell gene remedy which makes use of lentivector transduced hematopoietic stem and progenitor cells to ship useful UBE3A to affected cells. We have now demonstrated each the prevention and reversal of Angelman syndrome phenotypes upon transplantation and engraftment of human CD34+ cells transduced with a Ube3a lentivector in a novel immunodeficient Ube3amat-/pat+ IL2rg-/y mouse mannequin of Angelman syndrome.
A major enchancment in motor and cognitive behavioral assays in addition to normalized delta energy measured by EEG was noticed in neonates and adults transplanted with the gene modified cells. Human hematopoietic profiles noticed within the lymphoid organs by detection of human immune cells had been regular.
Expression of UBE3A was detected within the brains of the grownup therapy group following immunohistochemical staining illustrating engraftment of the gene modified cells expressing UBE3A within the mind. As demonstrated with our information, this stem cell gene remedy method affords a promising therapy technique for Angelman syndrome, not requiring a vital therapy window.
ZVex™, a dendritic-cell-tropic lentivector, primes protecting antitumor T cell responses which can be considerably boosted utilizing heterologous vaccine modalities
Therapeutic most cancers vaccines should induce excessive ranges of tumor-specific cytotoxic CD8 T cells to be efficient. We present right here that tumor-antigen particular effector and reminiscence T cell responses primed with a non-integrating, dendritic-cell focused lentiviral vector (ZVex™) could possibly be boosted considerably by both adjuvanted recombinant protein, adenoviral vectors, or self-replicating RNA.
These heterologous prime-boost regimens additionally supplied considerably higher safety in murine tumor fashions. In distinction, homologous prime-boost regimens, or utilizing the lentiviral vector as a lift, resulted in decrease T cell responses with restricted therapeutic efficacy. Heterologous prime-boost regimens that make the most of ZVex because the prime could also be enticing modalities for therapeutic most cancers vaccines.
Extremely environment friendly ‘hit-and-run’ genome modifying with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts
The appliance of gene-editing know-how is presently restricted by the dearth of protected and environment friendly strategies to ship RNA-guided endonucleases to focus on cells. We engineered lentivirus-based nanoparticles to co-package the U6-sgRNA template and the CRISPR-associated protein 9 (Cas9) fused with a virion-targeted protein Vpr (Vpr.Prot.Cas9), for simultaneous supply to cells.
Equal spatiotemporal management of the vpr.prot.cas9 and gag/pol gene expression (the presence of Rev responsive aspect, RRE) drastically enhanced the encapsidation of the fusion protein and resulted within the manufacturing of extremely environment friendly lentivector nanoparticles. Transduction of the unconcentrated, Vpr.Prot.Cas9-containing vectors led to >98% disruption of the EGFP gene in reporter HEK293-EGFP cells with minimal cytotoxicity.
Moreover, we detected indels within the focused endogenous loci at frequencies of as much as 100% in cell traces derived from lymphocytes and monocytes and as much as 15% in major CD4+ T cells by high-throughput sequencing. This method might present a platform for the environment friendly, dose-controlled and tissue-specific supply of genome modifying enzymes to cells and it could be appropriate for simultaneous endogenous gene disruption and a transgene supply.
A single lentivector DNA based mostly immunization accommodates a late heterologous SIVmac251 mucosal problem an infection.
Number of typical vaccine methods examined towards HIV-1 have did not induce safety towards HIV acquisition or sturdy management of viremia. Subsequently, modern methods that may induce lengthy lasting protecting immunity towards HIV continual an infection are wanted. Lately, we developed an integration-defective HIV lentiDNA vaccine that undergoes a single cycle of replication in goal cells wherein most viral antigens are produced.
A single immunization with such lentiDNA induced long-lasting T-cell and modest antibody responses in cynomolgus macaques. Right here eighteen months after this single immunization, all animals had been subjected to repeated low dose intra-rectal challenges with a heterologous pathogenic SIVmac251 isolate.
Though the viral set level in SIVmac-infected cynomolgus is often decrease than that seen in Indian rhesus macaques, the vaccinated group of macaques displayed a two log discount of peak of viremia adopted by a progressive and sustained management of virus replication relative to manage animals.
This antiviral management correlated with antigen-specific CD4+ and CD8+ T cells with excessive capability of recall responses comprising effector and central reminiscence T cells but additionally reminiscence T cell precursors. That is the primary description of SIV management in NHP mannequin contaminated at 18 months following a single immunization with a non-integrative single cycle lentiDNA HIV vaccine.
Whereas not delivering sterilizing immunity, our single immunization technique with a single-cycle lentivector DNA vaccine seems to offer an fascinating and protected vaccine platform that warrants additional exploration.
Vesicular stomatitis virus Indiana pressure glycoprotein (VSVind.G) mediates broad tissue tropism and environment friendly mobile uptake. Lentiviral vectors (LVs) are notably promising, as they’ll effectively transduce non-dividing cells and facilitate steady genomic transgene integration; due to this fact, LVs have an infinite untapped potential for gene remedy purposes, however the improvement of humoral and cell-mediated anti-vector responses might prohibit their efficacy.
We hypothesized that G proteins from totally different members of the vesiculovirus genus may enable the technology of a panel of serotypically distinct LV pseudotypes with potential for repeated in vivo administration.
We discovered that mice hyperimmunized with VSVind.G weren’t transduced to any important diploma following intravenous injection of LVs with VSVind.G envelopes, in keeping with the thesis that a number of LV administrations would doubtless be blunted by an adaptive immune response.
Excitingly, bioluminescence imaging research demonstrated that the VSVind-neutralizing response could possibly be evaded by LV pseudotyped with Piry and, to a lesser extent, Cocal virus glycoproteins. Heterologous dosing regimens utilizing viral vectors and oncolytic viruses with Piry and Cocal envelopes might signify a novel technique to attain repeated vector-based interventions, unfettered by pre-existing anti-envelope antibodies.
Characterizing the encapsulation and launch of lentivectors and adeno-associated vectors from degradable alginate hydrogels.
Gene remedy utilizing viral vectors has been licensed for scientific use each within the European Union and the USA. Lentivectors (LV) and adeno-associated vectors (AAV) are two promising and FDA accredited gene-therapy viral vectors. Many future purposes of those vectors will profit from focusing on particular areas of curiosity throughout the physique.
Subsequently, constructing on the early success of those vectors might rely upon discovering efficient supply programs to localize therapeutic administration. Degradable alginate hydrogels have been examined as interesting supply automobiles for the managed supply of vector payloads. On this research, we examine the flexibility of two totally different degradable alginate hydrogel formulations to effectively ship LV and AAV.
We suggest that launch charges of viral vectors are depending on the bodily properties of each the hydrogels and vectors. Right here, we reveal that the preliminary power and degradation charge of alginate hydrogels supplies levers of management for tuning LV launch however don’t present management within the launch of AAV.
Whereas each alginate formulations used confirmed sustained launch of each LV and AAV, LV launch was proven to be depending on alginate hydrogel degradation, whereas AAV launch was largely ruled by diffusive mechanisms.
Mcoln1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL512633 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
MCOLN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV632485 | ABM | 1.0 ug DNA | EUR 818.4 |
MCOLN2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV632489 | ABM | 1.0 ug DNA | EUR 818.4 |
MCOLN2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV632490 | ABM | 1.0 ug DNA | EUR 818.4 |
MCOLN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV632486 | ABM | 1.0 ug DNA | EUR 818.4 |
MCOLN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV632487 | ABM | 1.0 ug DNA | EUR 888 |
MCOLN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV632488 | ABM | 1.0 ug DNA | EUR 888 |
Mcoln3 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701568 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Mcoln2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL703592 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
MCOLN3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303305 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
MCOLN2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303306 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Mcoln2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504128 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Mcoln3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL506106 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Mcoln1 ORF Vector (Rat) (pORF) |
|||
| ORF070382 | ABM | 1.0 ug DNA | EUR 607.2 |
Mcoln1 ORF Vector (Mouse) (pORF) |
|||
| ORF049952 | ABM | 1.0 ug DNA | EUR 607.2 |
MCOLN1 ORF Vector (Human) (pORF) |
|||
| ORF006340 | ABM | 1.0 ug DNA | EUR 114 |
MCOLN1 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV281528 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Rat) (pPB-C-His) |
|||
| PV281526 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Rat) (pPB-N-His) |
|||
| PV281527 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Rat) (pPM-C-His) |
|||
| PV281529 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Human) (pPM-C-HA) |
|||
| PV025359 | ABM | 500 ng | EUR 394.8 |
MCOLN1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV199808 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Human) (pPB-C-His) |
|||
| PV025357 | ABM | 500 ng | EUR 394.8 |
MCOLN1 Protein Vector (Human) (pPB-N-His) |
|||
| PV025358 | ABM | 500 ng | EUR 394.8 |
MCOLN1 Protein Vector (Human) (pPM-C-His) |
|||
| PV025360 | ABM | 500 ng | EUR 394.8 |
MCOLN1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV199806 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV199807 | ABM | 500 ng | EUR 723.6 |
MCOLN1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV199809 | ABM | 500 ng | EUR 723.6 |
Mcoln1 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL704498V | Origene Technologies GmbH | 500 ul each | Ask for price |
MCOLN1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL303307V | Origene Technologies GmbH | 500 ul each | Ask for price |
Mcoln1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL512633V | Origene Technologies GmbH | 500 ul each | Ask for price |
Lenti ORF clone of Mcoln1 (mGFP-tagged) - Mouse mucolipin 1 (Mcoln1) |
|||
| MR225390L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Mcoln1 (Myc-DDK-tagged) - Mouse mucolipin 1 (Mcoln1) |
|||
| MR225390L3 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 |
|||
| CSB-CL872417HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
Mcoln1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6717101 | ABM | 3 x 1.0 ug | EUR 406.8 |
MCOLN1 (untagged)-Human mucolipin 1 (MCOLN1) |
|||
| SC319381 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Mcoln1 (mGFP-tagged ORF) - Rat mucolipin 1 (Mcoln1), (10 ug) |
|||
| RR212292L4 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 sgRNA CRISPR Lentivector set (Human) |
|||
| K1281301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Mcoln1 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4111301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Lenti ORF particles, Mcoln1 (GFP-tagged) - Mouse mucolipin 1 (Mcoln1), 200ul, >10^7 TU/mL |
|||
| MR225390L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, MCOLN1 (mGFP-tagged) - Human mucolipin 1 (MCOLN1), 200ul, >10^7 TU/mL |
|||
| RC201010L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, MCOLN1 (mGFP-tagged) - Human mucolipin 1 (MCOLN1), 200ul, >10^7 TU/mL |
|||
| RC201010L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Mcoln1 (Myc-DDK-tagged ORF) - Rat mucolipin 1 (Mcoln1), (10 ug) |
|||
| RR212292L3 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 (GFP-tagged) - Human mucolipin 1 (MCOLN1) |
|||
| RG201010 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Mcoln1 (GFP-tagged ORF) - Rat mucolipin 1 (Mcoln1), 200ul, >10^7 TU/mL |
|||
| RR212292L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Mcoln1 (untagged) - Mouse mucolipin 1 (Mcoln1), (10ug) |
|||
| MC219324 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, MCOLN1 (Myc-DDK tagged) - Human mucolipin 1 (MCOLN1), 200ul, >10^7 TU/mL |
|||
| RC201010L1V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, MCOLN1 (Myc-DDK tagged) - Human mucolipin 1 (MCOLN1), 200ul, >10^7 TU/mL |
|||
| RC201010L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Mcoln1 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR704498 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Lenti ORF particles, Mcoln1 (Myc-DDK-tagged) - Mouse mucolipin 1 (Mcoln1), 200ul, >10^7 TU/mL |
|||
| MR225390L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Mcoln1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6717102 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6717103 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6717104 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR512633 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
MCOLN1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR303307 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
MCOLN1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1281302 | ABM | 1.0 ug DNA | EUR 184.8 |
MCOLN1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1281303 | ABM | 1.0 ug DNA | EUR 184.8 |
MCOLN1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1281304 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4111302 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4111303 | ABM | 1.0 ug DNA | EUR 184.8 |
Mcoln1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4111304 | ABM | 1.0 ug DNA | EUR 184.8 |
MCOLN1 siRNA |
|||
| 20-abx923751 | Abbexa |
|
|
MCOLN1 siRNA |
|||
| 20-abx923752 | Abbexa |
|
|
Lenti ORF particles, Mcoln1 (Myc-DDK-tagged ORF) - Rat mucolipin 1 (Mcoln1), 200ul, >10^7 TU/mL |
|||
| RR212292L3V | Origene Technologies GmbH | 200 µl | Ask for price |
MCOLN1 Peptide |
|||
| MBS3227499-01mg | MyBiosource | 0.1mg | EUR 180 |
MCOLN1 Peptide |
|||
| MBS3227499-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
Mcoln1 (GFP-tagged) - Mouse mucolipin 1 (Mcoln1), (10ug) |
|||
| MG225390 | Origene Technologies GmbH | 10 µg | Ask for price |
Mcoln1 (Myc-DDK-tagged) - Mouse mucolipin 1 (Mcoln1) |
|||
| MR225390 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 (Myc-DDK-tagged)-Human mucolipin 1 (MCOLN1) |
|||
| RC201010 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 Antibody |
|||
| GWB-D34618 | GenWay Biotech | 0.05 mg | Ask for price |
Mcoln1 (untagged ORF) - Rat mucolipin 1 (Mcoln1), (10 ug) |
|||
| RN212292 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) |
|||
| MBS6007836-02mL | MyBiosource | 0.2(mL | EUR 695 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) |
|||
| MBS6007836-5x02mL | MyBiosource | 5x0.2mL | EUR 2975 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (AP) |
|||
| MBS6319738-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (AP) |
|||
| MBS6319738-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (PE) |
|||
| MBS6319748-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (PE) |
|||
| MBS6319748-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (APC) |
|||
| MBS6319739-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (APC) |
|||
| MBS6319739-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (FITC) |
|||
| MBS6319741-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (FITC) |
|||
| MBS6319741-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
MCOLN1 cDNA Clone |
|||
| MBS1270766-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 330 |
MCOLN1 cDNA Clone |
|||
| MBS1270766-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 1430 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (Biotin) |
|||
| MBS6319740-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (Biotin) |
|||
| MBS6319740-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
MCOLN1 siRNA (Mouse) |
|||
| MBS8202237-15nmol | MyBiosource | 15nmol | EUR 405 |
MCOLN1 siRNA (Mouse) |
|||
| MBS8202237-30nmol | MyBiosource | 30nmol | EUR 565 |
MCOLN1 siRNA (Mouse) |
|||
| MBS8202237-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
MCOLN1 siRNA (Human) |
|||
| MBS8229712-15nmol | MyBiosource | 15nmol | EUR 405 |
MCOLN1 siRNA (Human) |
|||
| MBS8229712-30nmol | MyBiosource | 30nmol | EUR 565 |
MCOLN1 siRNA (Human) |
|||
| MBS8229712-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
Mcoln1 (Myc-DDK-tagged ORF) - Rat mucolipin 1 (Mcoln1), (10 ug) |
|||
| RR212292 | Origene Technologies GmbH | 10 µg | Ask for price |
MCOLN1 cloning plasmid |
|||
| CSB-CL872417HU-10ug | Cusabio | 10ug | EUR 451.2 |
|
Description: A cloning plasmid for the MCOLN1 gene. |
|||
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6717105 | ABM | 3 x 1.0 ug | EUR 451.2 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 405) |
|||
| MBS6319743-01mL | MyBiosource | 0.1mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 405) |
|||
| MBS6319743-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 490) |
|||
| MBS6319744-01mL | MyBiosource | 0.1mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 490) |
|||
| MBS6319744-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 550) |
|||
| MBS6319745-01mL | MyBiosource | 0.1mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 550) |
|||
| MBS6319745-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 650) |
|||
| MBS6319746-01mL | MyBiosource | 0.1mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 650) |
|||
| MBS6319746-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 750) |
|||
| MBS6319747-01mL | MyBiosource | 0.1mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (MaxLight 750) |
|||
| MBS6319747-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
MCOLN1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K1281305 | ABM | 3 x 1.0 ug | EUR 451.2 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K4111305 | ABM | 3 x 1.0 ug | EUR 451.2 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (Azide free) (HRP) |
|||
| MBS6319742-02mL | MyBiosource | 0.2mL | EUR 980 |
MCOLN1, CT (MCOLN1, ML4, Mucolipin-1, MG-2, Mucolipidin) (Azide free) (HRP) |
|||
| MBS6319742-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
Mouse Mcoln1 ELISA Kit |
|||
| EF015572 | Nova Lifetech | 96tests | EUR 566 |
Human MCOLN1 ELISA KIT |
|||
| EF005299 | Nova Lifetech | 96tests | EUR 566 |
MCOLN1 Antibody (C-term) |
|||
| MBS9205163-008mL | MyBiosource | 0.08mL | EUR 210 |
MCOLN1 Antibody (C-term) |
|||
| MBS9205163-04mL | MyBiosource | 0.4mL | EUR 430 |
MCOLN1 Antibody (C-term) |
|||
| MBS9205163-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6717106 | ABM | 1.0 ug DNA | EUR 200.4 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6717107 | ABM | 1.0 ug DNA | EUR 200.4 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6717108 | ABM | 1.0 ug DNA | EUR 200.4 |
Mouse MCOLN1 shRNA Plasmid |
|||
| 20-abx979279 | Abbexa |
|
|
Human MCOLN1 shRNA Plasmid |
|||
| 20-abx961390 | Abbexa |
|
|
Mcoln3 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL701568V | Origene Technologies GmbH | 500 ul each | Ask for price |
Mcoln2 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL703592V | Origene Technologies GmbH | 500 ul each | Ask for price |
MCOLN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K1281306 | ABM | 1.0 ug DNA | EUR 200.4 |
MCOLN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K1281307 | ABM | 1.0 ug DNA | EUR 200.4 |
MCOLN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K1281308 | ABM | 1.0 ug DNA | EUR 200.4 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K4111306 | ABM | 1.0 ug DNA | EUR 200.4 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K4111307 | ABM | 1.0 ug DNA | EUR 200.4 |
Mcoln1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K4111308 | ABM | 1.0 ug DNA | EUR 200.4 |
Human MCOLN1 Protein Lysate |
|||
| MBS8415063-002mg | MyBiosource | 0.02mg | EUR 365 |
Human MCOLN1 Protein Lysate |
|||
| MBS8415063-5x002mg | MyBiosource | 5x0.02mg | EUR 1410 |
Mucolipin 1 (MCOLN1) Antibody |
|||
| abx027461-400ul | Abbexa | 400 ul | EUR 627.6 |
Mucolipin 1 (MCOLN1) Antibody |
|||
| abx027461-80l | Abbexa | 80 µl | EUR 343.2 |
Mucolipin 1 (MCOLN1) Antibody |
|||
| abx027461-400l | Abbexa | 400 µl | EUR 518.75 |
MCOLN1 Recombinant Protein (Rat) |
|||
| RP211142 | ABM | 100 ug | Ask for price |
AAP35307-100UG - MCOLN1 Peptide |
|||
| AAP35307-100UG | Aviva Systems Biology | 100ug | EUR 99 |
MCOLN3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL303305V | Origene Technologies GmbH | 500 ul each | Ask for price |
MCOLN2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL303306V | Origene Technologies GmbH | 500 ul each | Ask for price |
Mcoln2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL504128V | Origene Technologies GmbH | 500 ul each | Ask for price |
Mcoln3 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL506106V | Origene Technologies GmbH | 500 ul each | Ask for price |
MCOLN1 Recombinant Protein (Human) |
|||
| RP019018 | ABM | 100 ug | Ask for price |
MCOLN1 Recombinant Protein (Mouse) |
|||
| RP149852 | ABM | 100 ug | Ask for price |
MCOLN1 Rabbit Polyclonal Antibody |
|||
| E10G35086 | EnoGene | 100 μl | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
Lenti ORF clone of Human mucolipin 1 (MCOLN1), mGFP tagged |
|||
| RC201010L2 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human mucolipin 1 (MCOLN1), mGFP tagged |
|||
| RC201010L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Human MCOLN1 knockout cell line |
|||
| ABC-KH9118 | AcceGen | 1 vial | Ask for price |
|
Description: Human MCOLN1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Altogether, this research demonstrates alginate’s use as a attainable supply platform for LV and, for the primary time, AAV – highlighting the potential of injectable degradable alginate hydrogels for use as a flexible supply software in gene remedy purposes.
